NYSEAMERICAN:ASTAsterias Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Asterias Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.0020 0.00 (0.00 %) (As of 07/10/2019) Add Compare Share Today's Range$0.00Now: $0.00▼$0.0050-Day Range N/A52-Week Range$0.51Now: $0.00▼$2.05Volume1,000 shsAverage Volume136,653 shsMarket Capitalization$111,318.00P/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Asterias Biotherapeutics. Previous Next 2.6 Community Rank Outperform VotesAsterias Biotherapeutics has received 139 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAsterias Biotherapeutics has received 127 “underperform” votes. (Add your “underperform” vote.)Community SentimentAsterias Biotherapeutics has received 52.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote “Outperform” if you believe AST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAsterias Biotherapeutics does not currently pay a dividend.Dividend GrowthAsterias Biotherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Asterias Biotherapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:AST Previous SymbolNYSEMKT:AST CUSIPN/A CIKN/A Webasteriasbiotherapeutics.com Phone+1-510-4563805Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares55,659,000Market Cap$111,318.00 Next Earnings DateN/A OptionableOptionable $0.0020 0.00 (0.00 %) (As of 07/10/2019) 30 days | 90 days | 365 days | Advanced Chart Receive AST News and Ratings via Email Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter. Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions How were Asterias Biotherapeutics' earnings last quarter? Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its quarterly earnings data on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analysts' expectations of $2.81 million. View Asterias Biotherapeutics' earnings history. Has Asterias Biotherapeutics been receiving favorable news coverage? News coverage about AST stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Asterias Biotherapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Asterias Biotherapeutics. Who are some of Asterias Biotherapeutics' key competitors? Some companies that are related to Asterias Biotherapeutics include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE) and Canada House Wellness Group (CHV). View all competitors. What other stocks do shareholders of Asterias Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include BioTime (BTX), Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), CorMedix (CRMD), Freeport-McMoRan (FCX), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO) and 22nd Century Group (XXII). Who are Asterias Biotherapeutics' key executives? Asterias Biotherapeutics' management team includes the following people: Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)Dr. Katharine E. Spink, Consultant (Age 45)Mr. Stephen L. Cartt, Advisor & Director (Age 56)Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43) What is Asterias Biotherapeutics' stock symbol? Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST." How do I buy shares of Asterias Biotherapeutics? Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Asterias Biotherapeutics' stock price today? One share of AST stock can currently be purchased for approximately $0.00. How big of a company is Asterias Biotherapeutics? Asterias Biotherapeutics has a market capitalization of $111,318.00. What is Asterias Biotherapeutics' official website? The official website for Asterias Biotherapeutics is asteriasbiotherapeutics.com. How can I contact Asterias Biotherapeutics? Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
